These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16689922)

  • 1. Adverse events following immunization attributable to measles vaccine are rare.
    Araki D; Bruno J; Salama P; Sadeed A; Sadozai N; Nandy R; Cairns L; Lievano F
    Disasters; 2006 Jun; 30(2):270-2. PubMed ID: 16689922
    [No Abstract]   [Full Text] [Related]  

  • 2. Atypical measles following immunization with killed measles vaccine.
    McLean DM; Kettyls GD; Hingston J; Moore PS; Paris RP; Rigg JM
    Can Med Assoc J; 1970 Oct; 103(7):743-4. PubMed ID: 5506110
    [No Abstract]   [Full Text] [Related]  

  • 3. Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004.
    Nakayama T; Onoda K
    Vaccine; 2007 Jan; 25(3):570-6. PubMed ID: 16945455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitizing versus immunizing properties of inactivated measles vaccine.
    Wilson S; Aprile MA
    Prog Immunobiol Stand; 1970; 4():657-60. PubMed ID: 4991597
    [No Abstract]   [Full Text] [Related]  

  • 5. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003.
    Asatryan A; Pool V; Chen RT; Kohl KS; Davis RL; Iskander JK;
    Vaccine; 2008 Feb; 26(9):1166-72. PubMed ID: 18255204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaphylaxis following single component measles and rubella immunisation.
    Erlewyn-Lajeunesse M; Manek R; Lingam R; Finn A; Emond A
    Arch Dis Child; 2008 Nov; 93(11):974-5. PubMed ID: 18941022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivated measles vaccine and the risk of adverse events.
    Nossal GJ
    Bull World Health Organ; 2000; 78(2):224-5. PubMed ID: 10743293
    [No Abstract]   [Full Text] [Related]  

  • 8. Exaggerated natural measles following attenuated virus immunization: a refraction--toxic shock syndrome.
    St Geme JW; Bush BM; George BL
    Pediatrics; 1981 Jun; 67(6):942. PubMed ID: 7232067
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk of serious neurologic disease after immunization of young children in Britain and Ireland.
    Ward KN; Bryant NJ; Andrews NJ; Bowley JS; Ohrling A; Verity CM; Ross EM; Miller E
    Pediatrics; 2007 Aug; 120(2):314-21. PubMed ID: 17671057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinguishing between primary measles infection and vaccine failure reinfection by IgG avidity assay.
    Hamkar R; Mahmoodi M; Nategh R; Jelyani KN; Eslami MB; Mohktari-Azad T
    East Mediterr Health J; 2006 Nov; 12(6):775-82. PubMed ID: 17333822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of the effect of measles vaccination on the epidemiology of SSPE.
    Campbell H; Andrews N; Brown KE; Miller E
    Int J Epidemiol; 2007 Dec; 36(6):1334-48. PubMed ID: 18037676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paroxysmal cold haemoglobinuria following measles immunization.
    Bunch C; Schwartz FC; Bird GW
    Arch Dis Child; 1972 Apr; 47(252):299-300. PubMed ID: 5023480
    [No Abstract]   [Full Text] [Related]  

  • 13. Killed-measles-virus vaccine.
    Fulginiti VA; Kempe CH
    Lancet; 1967 Aug; 2(7513):468. PubMed ID: 4166115
    [No Abstract]   [Full Text] [Related]  

  • 14. Is there a link between measles and inflammatory bowel disease?
    Feeney M; Snook J
    Ital J Gastroenterol Hepatol; 1998 Aug; 30(4):383-4. PubMed ID: 9789133
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants.
    Gatchalian S; Yao Y; Zhou B; Zhang L; Yoksan S; Kelly K; Neuzil KM; Yaïch M; Jacobson J
    Vaccine; 2008 Apr; 26(18):2234-41. PubMed ID: 18394765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nationwide measles epidemic in Ukraine: the effect of low vaccine effectiveness.
    Velicko I; Müller LL; Pebody R; Gergonne B; Aidyralieva C; Kostiuchenko N; Spika JS
    Vaccine; 2008 Dec; 26(52):6980-5. PubMed ID: 18805455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hemolytic-uremic syndrome after measles].
    Herrera González I; Olvera Hidalgo C; Marín Palomares MT; Lecona Desmot L; García Torres R; Burgos Fuentes VR
    Bol Med Hosp Infant Mex; 1980; 37(6):1245-53. PubMed ID: 7193473
    [No Abstract]   [Full Text] [Related]  

  • 18. Severe cutaneous reaction following measles immunization.
    Inamadar AC; Patil SS; Palit A
    Int J Dermatol; 2009 Aug; 48(8):873-4. PubMed ID: 19659866
    [No Abstract]   [Full Text] [Related]  

  • 19. Experience with measles immunization. Alum-absorbed killed measles-virus vaccine and live measles-virus vaccine challenge.
    KARELITZ S; PECK FB
    Am J Dis Child; 1962 Mar; 103():427-9. PubMed ID: 14453928
    [No Abstract]   [Full Text] [Related]  

  • 20. Heterologous prime-boost strategy to immunize very young infants against measles: pre-clinical studies in rhesus macaques.
    Pasetti MF; Resendiz-Albor A; Ramirez K; Stout R; Papania M; Adams RJ; Polack FP; Ward BJ; Burt D; Chabot S; Ulmer J; Barry EM; Levine MM
    Clin Pharmacol Ther; 2007 Dec; 82(6):672-85. PubMed ID: 17971812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.